Page last updated: 2024-09-04

tipifarnib and Erythremia

tipifarnib has been researched along with Erythremia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A	1
Cassinat, B; Chomienne, C; Gervais, N; Larghero, J; Padua, RA; Rain, JD; Rousselot, P; Schlageter, MH	1
Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W	1

Trials

1 trial(s) available for tipifarnib and Erythremia

Article	Year
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia, 2007, Volume: 21, Issue:9 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome	2007

Article

Year

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Leukemia, 2007, Volume: 21, Issue:9

Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome

2007

Other Studies

2 other study(ies) available for tipifarnib and Erythremia

Article	Year
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia, 2003, Volume: 17, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential	2003
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood, 2005, May-01, Volume: 105, Issue:9 Topics: Alkyl and Aryl Transferases; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Farnesyltranstransferase; Humans; Polycythemia Vera; Quinolones	2005

Article

Year

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Leukemia, 2003, Volume: 17, Issue:5

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential

2003

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

Blood, 2005, May-01, Volume: 105, Issue:9

Topics: Alkyl and Aryl Transferases; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Farnesyltranstransferase; Humans; Polycythemia Vera; Quinolones

2005